Suchergebnisse - "van de Donk, Niels W C J"

PubPharm (217)

81

Monoclonal Antibodies and Antibody Drug Conjugates in Multiple Myeloma

enthalten in: Cancers | 2021

von Radocha, J. | van de Donk, N. | Weisel, K.

82

Deletion 17p : a matter of size and number?

enthalten in: Blood | 2021

von Zweegman, S. | van de Donk, N.

CommentOn: Blood. 2021 Mar 4;137(9):1192-1195. - PMID 33080624

83

Deep immune profiling of patients treated with lenalidomide and dexamethasone with or without daratumumab

enthalten in: Leukemia | 2021

von Casneuf, T. | Adams, H. | van de Donk, N. | +20

84

Evaluation of Cardiac Repolarization in the Randomized Phase 2 Study of Intermediate- or High-Risk Smoldering Multiple Myeloma Patients Treated with Daratumumab Monotherapy

enthalten in: Advances in therapy | 2021

von Chari, A. | Munder, M. | Weisel, K. | +18

85

First-line treatment and survival of newly diagnosed primary plasma cell leukemia patients in the Netherlands : a population-based study, 1989-2018

enthalten in: Blood cancer journal | 2021

von Brink, M. | Visser, O. | Zweegman, S. | +4

86

Multiple myeloma

enthalten in: Lancet (London, England) | 2021

von van de Donk, N. | Pawlyn, C. | Yong, K.

87

Preclinical Evaluation of Invariant Natural Killer T Cells Modified with CD38 or BCMA Chimeric Antigen Receptors for Multiple Myeloma

enthalten in: International journal of molecular sciences | 2021

von Poels, R. | Drent, E. | Lameris, R. | +6

88

Evaluation of Cardiac Repolarization in the Randomized Phase 2 Study of Intermediate- or High-Risk Smoldering Multiple Myeloma Patients Treated with Daratumumab Monotherapy

enthalten in: Advances in therapy | 2021

von Chari, A. | Munder, M. | Weisel, K. | +18

89

Evaluation of Cardiac Repolarization in the Randomized Phase 2 Study of Intermediate- or High-Risk Smoldering Multiple Myeloma Patients Treated with Daratumumab Monotherapy

enthalten in: Advances in therapy | 2021

von Chari, A. | Munder, M. | Weisel, K. | +18

90

Evaluation of Cardiac Repolarization in the Randomized Phase 2 Study of Intermediate- or High-Risk Smoldering Multiple Myeloma Patients Treated with Daratumumab Monotherapy

enthalten in: Advances in therapy | 2021

von Chari, A. | Munder, M. | Weisel, K. | +18